一项关于ADME代理物基因变异对DD217药理动力学和安全性概况作用的调查研究
Dmitry A Sychev1,2, Sherzod P Abdullaev1,2, Anastasia V Rudik3
1Federal State Budgetary Research Institution «Russian Research Center of Surgery Named After Academician B.V. Petrovsky», Abrikosovsky Lane, 2, 119991 Moscow, Russia.
Pharmaceuticals (Basel, Switzerland)
|November 27, 2025
概括
这项研究调查了遗传变异如何影响药物DD217,一种新的直接口服抗凝剂 (DOAC). 关键发现表明,CYP2C9变异影响药物吸收速度,而ABCB1基因变异影响药物水平和潜在的血栓形成风险.
科学领域:
- 药物遗传学 药物遗传学
- 药物新陈代谢 药物新陈代谢
- 血栓塞栓性疾病预防 预防
背景情况:
- 直接口服抗凝剂 (DOAC) 在有效性和安全性方面表现出显著的个体间差异.
- DD217是一种新的口服直接XA因子抑制剂,具有已证明的抗凝活性.
- 对于DD217没有先前的药物遗传学数据,因此需要对其药物动力学和结果的遗传影响进行调查.
研究的目的:
- 评估DD217药理动力学 (PK) 和临床结果变化的药理基因基础.
- 调查CYP2C基因变异和P-糖蛋白 (ABCB1) 在DD217处置中的潜在作用.
- 为了将基因变异与PK参数 (Tmax,AUC,Cmax) 和不良事件 (血栓,出血) 相关联.
主要方法:
- 在接受全膝关节整形手术的52名患者中,对CYP2C9,CYP2C19,CYP2C8,CYP3A4,CYP3A5和ABCB1进行基因定型.
- 在34名接受DD217 (每天40毫克或60毫克) 的患者中评估了PK参数 (Tmax,AUC,Cmax).
- 在模型中预测了CYP2C和ABCB1的参与;分析了与PK和不良事件的遗传关联.
主要成果:
- 功能减弱的CYP2C9等位基因与60毫克组的Tmax显著缩短有关 (p=0.005).
- ABCB1多态 (rs1045642,rs2032582) 与改变的全身暴露 (AUC,Cmax) 相相关.
- 在40毫克剂量 (p=0.038) 发生血栓事件的患者中,特定的ABCB1单元型 (C-G-C-T) 更频繁.
结论:
- 这项研究是第一个对DD217的药物遗传学评估,揭示了CYP2C9变体与早期PK之间的关联.
- ABCB1多态度调节DD217的系统暴露,并可能影响血栓形成风险,与in silico预测保持一致.
- 早期的药物遗传学评估对于开发新的DOACs至关重要,尽管样本大小有限.
关键词:
ABCB1 (P-葡萄糖蛋白) 是一种蛋白质.DD217 DD217 DD217 这是一个很大的问题.在Dimolegin的公司.直接的口服抗凝剂是直接的口服抗凝剂.遗传学 遗传学 遗传学 是一个在的中.药物遗传学 药物遗传学药物动力学 药物动力学更多相关视频
相关概念视频
Dosage Regimen: Individualization
156
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
156
Nonlinear Pharmacokinetics: Role of Transporters
262
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
262
Factors Affecting Drug Biotransformation: Biological
501
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
501
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
615
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
615
Pharmacokinetics: Overview
8.7K
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV)...
8.7K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241


